Slipping Gears in the Medical Industry The latest market fluctuations have left investors and analysts scrambling to make sense of the recent downturns at Novartis and Boston Scientific.
Intel's potential price hike, while more predictable, is worth examining in light of these developments.
The Slippery Slope of Clinical Trials Novartis' three failures in one week have led to a crisis of confidence on Wall Street.